Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.More mature interim data to be presented at EASL following abstract data cuts earlier in the

GlobeNewswireMay 22 07:00

Buy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical Trials

TipRanksMay 16 05:29

Analysts Offer Insights on Healthcare Companies: Barinthus Biotherapeutics (BRNS) and GoodRx Holdings (GDRX)

TipRanksMay 14 03:01

Barinthus Biotherapeutics Q1 EPS $(0.40) Beats $(0.54) Estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.54) by 25.93 percent. This is a 16.67 percent increase over loss

BenzingaMay 13 07:19

Barinthus Biotherapeutics | 10-Q: Quarterly report

SEC announcementMay 13 07:19 · Announcements

Barinthus Biotherapeutics: Runway to Fund Operating Expenses, Capital Spending Needs Into 4Q 2025 >BRNS

Barinthus Biotherapeutics: Runway to Fund Operating Expenses, Capital Spending Needs Into 4Q 2025 >BRNS

Dow JonesMay 13 07:04